Sorrento Therapeutics Inc

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It operates through the Sorrento Therapeutics and Scilex segments. The Sorrento Therapeutics segment consists of developing a portfolio of next generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. The Scilex segment is largely organized around the company's non-opioid pain management operations. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

Biogen

3D Systems

Duke Energy

Ford Motor Company

Akebia Therapeutics

Harley-Davidson

Lexicon Pharmaceuticals

Vail Resorts

PulteGroup

With the trading day practically over, the broad markets were sliding into the weekend.

Biogen, 3D Systems, Duke Energy, Ford and More of Friday Afternoon's Analyst Calls

The biotech reported encouraging early results for one of its experimental COVID-19 therapies.

Why Sorrento Therapeutics Stock Is Skyrocketing Today

The stock price of Sorrento Therapeutics Inc (NASDAQ: SRNE) increased by 12.28% on Tuesday, January 26. This is why it happened.

SRNE Stock Price Increased 12.28%: Why It Happened

SAN DIEGO, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today positive preliminary results from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS). This ongoing study (PSC-CP-004) is a single arm, non-randomized Phase 1b study of the safety and preliminary efficacy of COVI-MSCs administered every other day for three infusions for a total of 1 x 106 cells/kg. The primary objective is to evaluate the safety of intravenous infusion of allogeneic adipose MSC cells in patients with COVID-19-induced ARD or ARDS. The secondary objective is to evaluate efficacy outcome variables to give guidance regarding the risk/benefit ratio in patients with COVID-19 respiratory distress.

Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients

Sorrento Therapeutics stock, a clinical stage biopharma company that develops treatments for cancer and neurodegenerative diseases among others, has rallied by a solid 42% over the last 10 trading days, while it is up 35% over the last 5 trading days. This can be attributed to the positive data.

What's Next For Sorrento After A 35% Move In Last 5 Trading Days?

Can this biotech finally demonstrate progress in its COVID-19 pipeline before it's too late?

Where Will Sorrento Therapeutics Be in 1 Year?

Sorrento Therapeutics, Inc. (SRNE) CEO Henry Ji Presents at B. Riley Virtual Oncology Conference (Transcript)

The biotech announced the presentation of encouraging data for its experimental COVID-19 antibody therapy STI-2020.

Why Sorrento Therapeutics Stock Jumped Today

SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced that it will be presenting preliminary results from an ongoing SARS-CoV-2 mutation surveillance program for its neutralizing antibodies currently in clinical and pre-clinical development for treatment of patients with COVID-19 disease.

Sorrento to Present Data Demonstrating STI-2020 Preserves Binding Against UK B.1.1.7 SARS-CoV-2 Mutated Spike Protein

Investors need to pay close attention to Sorrento (SRNE) stock based on the movements in the options market lately.

Do Options Traders Know Something About Sorrento (SRNE) Stock We Don't?

SAN DIEGO, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference:

Dr. Henry Ji to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 20, 2021

The stock price of Sorrento Therapeutics Inc (NASDAQ: SRNE) has received a price target of $30 from H.C. Wainwright.

SRNE Stock Price: $30 Target From H.C. Wainwright

Bionano Genomics

These Nasdaq Biotech Stocks Doubled in 2020. Here's Why They're Soaring on Friday

SAN DIEGO, Jan. 10, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference:

Dr. Henry Ji to Participate in the H.C. Wainwright Bioconnect 2021 Virtual Investor Conference

SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that a Marketing Authorization Application has been submitted by its agents in Mexico to Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), the health regulatory authority for Mexico, for its COVI-STIX rapid diagnostic test for the detection of the SARS-CoV-2 virus nucleocapsid antigen in nasal samples of patients, "Inmunoensayo de flujo lateral para la detección cualitativa de la proteína nucleocápside del SARS-CoV-2".

Sorrento Announces the Submission of a Marketing Authorization Application to COFEPRIS (Mexico) for COVI-STIX™ Rapid Detection Test of SARS-CoV-2 Viral Antigen

Sorrento Therapeutics is developing an antibodies injection and nose drops to fight Covid-19 and its variant strains.

Sorrento Therapeutics developing antibodies injection and nose drops to fight Covid-19

SAN DIEGO, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that an Emergency Use Authorization (EUA) Application has been submitted to the US Food and Drug Administration for its COVI-STIX rapid diagnostic test for the detection of the SARS-CoV-2 virus nucleocapsid antigen in nasal samples of patients.

Sorrento Announces It Has Submitted An Emergency Use Authorization (EUA) Application to the FDA for COVI-STIX™ Rapid Test for the Detection of SARS-CoV-2 Viral Antigen

Nearly a third of SRNE stock's float has been sold short. This sets up a catalyst for a short-term move, but avoid a long-term investment.

Sorrento Stock Is Little More Than a Day Trade Now

Sorrento just received a grant of up to $34 million from Washington, while multiple institutions own meaningful amounts of SRNE stock. The post Government and Institutional Support Are Positives for Sorrento Stock appeared first on InvestorPlace.

Government and Institutional Support Are Positives for Sorrento Stock

The new version is more potent, and therefore requires a lower dose.

Sorrento Therapeutics Cleared to Start Trial for Its Next-Generation Coronavirus Antibody Treatment

Infinity Pharma

Sorrento Therapeutics (NASDAQ: SRNE) shares are trading higher on Wednesday after the company announced it has received CLIA Licensure from the State of California that permits testing of clinical samples. Sorrento Therapeutics is a biotechnology company focused on the development of novel immunotherapies for oncology and autoimmune/inflammation diseases.

Why Sorrento And Infinity Are Moving Today

Sorrento Therapeutics is poised to roll out clinical testing trials in California. SRNE stock is up in pre-market trading on Wednesday as the country continues to post record Covid-19 diagnoses and hospitalizations.

SRNE Stock: California Testing Approval Stokes Sorrento Therapeutics

- RT-PCR Emergency Use Authorization (EUA)-approved test using nasal pharyngeal swab

Sorrento Receives Licensure From the State of California for Clinical Testing Laboratory (CLIA) Allowing for Clinical Sample Testing

Sorrento Therapeutics has seen SRNE stock close between $5.76 and $8.20 in the past month. Here's why it's time for investors to be careful.

Sorrento Therapeutics Remains a Buy Between $6 and $6.50

SRNE stock fell out of favor as bigger vaccine developers grabbed the headlines but that may change soon. The post Covid-19 Vaccine Makers Still Make Sense, Including Sorrento Therapeutics appeared first on InvestorPlace.

News for Sorrento Therapeutics Inc Stock (SRNE)